Development and validation of the HPLC–MS/MS method and its application to the pharmacokinetic study for the Mongolian drug Sendeng-4 in rat blood plasma
AbstractSendeng-4 is a Mongolian drug. The Mongolian people have been using it to treat rheumatoid arthritis. At present, an increasing number of Han people are paying attention to the anti-rheumatoid effect of Sendeng-4. However, information on the pharmacokinetics of Sendeng-4 is limited, which li...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-03-01
|
| Series: | Frontiers in Pharmacology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2025.1547415/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850218594957262848 |
|---|---|
| author | Pu Bai Pu Bai Pu Bai Yu Dong Yu Dong |
| author_facet | Pu Bai Pu Bai Pu Bai Yu Dong Yu Dong |
| author_sort | Pu Bai |
| collection | DOAJ |
| description | AbstractSendeng-4 is a Mongolian drug. The Mongolian people have been using it to treat rheumatoid arthritis. At present, an increasing number of Han people are paying attention to the anti-rheumatoid effect of Sendeng-4. However, information on the pharmacokinetics of Sendeng-4 is limited, which limits its wide application in China.ObjectiveLiquid chromatography–tandem mass spectrometry (LC–MS/MS) was established to study the pharmacokinetics of Sendeng-4.MethodMS/MS with a negative ionization mode (ESI-) and multiple reaction monitoring at m/z 300.95→193.09 and 317.08→192.10 were detected for (2R, 3R)-dihydromyricetin and myricetin, respectively. The pharmacokinetic parameters were analyzed by DAS 2.0.ResultThe results showed that the plasma concentration time (C–T) curves of (2R, 3R)-dihydromyricetin and myricetin showed double peaks. The Tmax value of (2R, 3R)-dihydromyricetin and myricetin in both groups was 3 h. In absorption, the AUC(0-∞) values of (2R, 3R)-dihydromyricetin and myricetin in the normal group and the arthritis model group were 16.151 ± 2.670 mg·h/L vs. 11.331 ± 0.749 mg·h/L and 2.626 ± 0.400 mg·h/L vs. 2.213 ± 0.388 mg·h/L, respectively. In the distribution, the Vz/F values of (2R, 3R)-dihydromyricetin and myricetin in the normal group and the arthritis model group were 8.212 L/kg vs. 1.744 L/kg and 5.252 L/kg vs. 10.568 L/kg, respectively. In metabolism, the MRT (0-∞) values of (2R, 3R)-dihydromyricetin and myricetin in the normal group and the arthritis model group were 6.848 h vs. 3.476 h and 5.661 h vs. 8.959 h, respectively. In excretion, the CLz/F values of (2R, 3R)-dihydromyricetin and myricetin in the normal group and the arthritis model group were 0.021 vs. 0.024 L/min/kg and 0.018 vs. 0.021 L/min/kg, respectively. There were significant variations in the absorption levels, distribution levels, and elimination rate of (2R, 3R)-dihydromyricetin and myricetin after the administration of Sendeng-4.ConclusionThe study laid the foundation for the subsequent study of pharmacokinetics of Sendeng-4 in humans. The results of this study will contribute to a better understanding of the activity and clinical application of Sendeng-4 and other related traditional Mongolian drug prescriptions. |
| format | Article |
| id | doaj-art-e607633daa9149b5b6653790d7d29d23 |
| institution | OA Journals |
| issn | 1663-9812 |
| language | English |
| publishDate | 2025-03-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Pharmacology |
| spelling | doaj-art-e607633daa9149b5b6653790d7d29d232025-08-20T02:07:40ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122025-03-011610.3389/fphar.2025.15474151547415Development and validation of the HPLC–MS/MS method and its application to the pharmacokinetic study for the Mongolian drug Sendeng-4 in rat blood plasmaPu Bai0Pu Bai1Pu Bai2Yu Dong3Yu Dong4Inner Mongolia Medical University, Hohhot, ChinaOrdos School of Clinical Medicine, Inner Mongolia Medical University, Ordos, ChinaEngineering Technology Research Center of Pharmacodynamic Substance and Quality Control of Mongolian Medicine in Inner Mongolia, Inner Mongolia Medical University, Hohhot, ChinaInner Mongolia Medical University, Hohhot, ChinaEngineering Technology Research Center of Pharmacodynamic Substance and Quality Control of Mongolian Medicine in Inner Mongolia, Inner Mongolia Medical University, Hohhot, ChinaAbstractSendeng-4 is a Mongolian drug. The Mongolian people have been using it to treat rheumatoid arthritis. At present, an increasing number of Han people are paying attention to the anti-rheumatoid effect of Sendeng-4. However, information on the pharmacokinetics of Sendeng-4 is limited, which limits its wide application in China.ObjectiveLiquid chromatography–tandem mass spectrometry (LC–MS/MS) was established to study the pharmacokinetics of Sendeng-4.MethodMS/MS with a negative ionization mode (ESI-) and multiple reaction monitoring at m/z 300.95→193.09 and 317.08→192.10 were detected for (2R, 3R)-dihydromyricetin and myricetin, respectively. The pharmacokinetic parameters were analyzed by DAS 2.0.ResultThe results showed that the plasma concentration time (C–T) curves of (2R, 3R)-dihydromyricetin and myricetin showed double peaks. The Tmax value of (2R, 3R)-dihydromyricetin and myricetin in both groups was 3 h. In absorption, the AUC(0-∞) values of (2R, 3R)-dihydromyricetin and myricetin in the normal group and the arthritis model group were 16.151 ± 2.670 mg·h/L vs. 11.331 ± 0.749 mg·h/L and 2.626 ± 0.400 mg·h/L vs. 2.213 ± 0.388 mg·h/L, respectively. In the distribution, the Vz/F values of (2R, 3R)-dihydromyricetin and myricetin in the normal group and the arthritis model group were 8.212 L/kg vs. 1.744 L/kg and 5.252 L/kg vs. 10.568 L/kg, respectively. In metabolism, the MRT (0-∞) values of (2R, 3R)-dihydromyricetin and myricetin in the normal group and the arthritis model group were 6.848 h vs. 3.476 h and 5.661 h vs. 8.959 h, respectively. In excretion, the CLz/F values of (2R, 3R)-dihydromyricetin and myricetin in the normal group and the arthritis model group were 0.021 vs. 0.024 L/min/kg and 0.018 vs. 0.021 L/min/kg, respectively. There were significant variations in the absorption levels, distribution levels, and elimination rate of (2R, 3R)-dihydromyricetin and myricetin after the administration of Sendeng-4.ConclusionThe study laid the foundation for the subsequent study of pharmacokinetics of Sendeng-4 in humans. The results of this study will contribute to a better understanding of the activity and clinical application of Sendeng-4 and other related traditional Mongolian drug prescriptions.https://www.frontiersin.org/articles/10.3389/fphar.2025.1547415/fullMongolian drugSendeng-4myricetinLC–MS/MSpharmacokinetic(2R, 3R)-dihydromyricetin |
| spellingShingle | Pu Bai Pu Bai Pu Bai Yu Dong Yu Dong Development and validation of the HPLC–MS/MS method and its application to the pharmacokinetic study for the Mongolian drug Sendeng-4 in rat blood plasma Frontiers in Pharmacology Mongolian drug Sendeng-4 myricetin LC–MS/MS pharmacokinetic (2R, 3R)-dihydromyricetin |
| title | Development and validation of the HPLC–MS/MS method and its application to the pharmacokinetic study for the Mongolian drug Sendeng-4 in rat blood plasma |
| title_full | Development and validation of the HPLC–MS/MS method and its application to the pharmacokinetic study for the Mongolian drug Sendeng-4 in rat blood plasma |
| title_fullStr | Development and validation of the HPLC–MS/MS method and its application to the pharmacokinetic study for the Mongolian drug Sendeng-4 in rat blood plasma |
| title_full_unstemmed | Development and validation of the HPLC–MS/MS method and its application to the pharmacokinetic study for the Mongolian drug Sendeng-4 in rat blood plasma |
| title_short | Development and validation of the HPLC–MS/MS method and its application to the pharmacokinetic study for the Mongolian drug Sendeng-4 in rat blood plasma |
| title_sort | development and validation of the hplc ms ms method and its application to the pharmacokinetic study for the mongolian drug sendeng 4 in rat blood plasma |
| topic | Mongolian drug Sendeng-4 myricetin LC–MS/MS pharmacokinetic (2R, 3R)-dihydromyricetin |
| url | https://www.frontiersin.org/articles/10.3389/fphar.2025.1547415/full |
| work_keys_str_mv | AT pubai developmentandvalidationofthehplcmsmsmethodanditsapplicationtothepharmacokineticstudyforthemongoliandrugsendeng4inratbloodplasma AT pubai developmentandvalidationofthehplcmsmsmethodanditsapplicationtothepharmacokineticstudyforthemongoliandrugsendeng4inratbloodplasma AT pubai developmentandvalidationofthehplcmsmsmethodanditsapplicationtothepharmacokineticstudyforthemongoliandrugsendeng4inratbloodplasma AT yudong developmentandvalidationofthehplcmsmsmethodanditsapplicationtothepharmacokineticstudyforthemongoliandrugsendeng4inratbloodplasma AT yudong developmentandvalidationofthehplcmsmsmethodanditsapplicationtothepharmacokineticstudyforthemongoliandrugsendeng4inratbloodplasma |